Tyra Biosciences (TYRA) Assets Average (2021 - 2026)

Tyra Biosciences has reported Assets Average for 6 years, with the latest figure at $347.3 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average fell 1.75% year-over-year to $347.3 million; the trailing twelve-month figure through Mar 2026 stood at $347.3 million (down 1.75% YoY), and the FY2025 full-year result was $323.1 million, up 9.63% from the prior year.
• Assets Average for Q1 2026 stood at $347.3 million, up from $292.2 million in the prior quarter.
• The five-year high for Assets Average was $398.6 million in Q2 2024, with the low at $232.1 million in Q4 2023.
• Historically, Assets Average has averaged $308.7 million across 5 years, with a median of $302.8 million in 2022.
• Annual changes were most pronounced in 2024 — Assets Average surged 60.3% — and 2025, when it slipped 21.46%.
• Tyra Biosciences' Assets Average stood at $271.1 million in 2022, then declined by 14.38% to $232.1 million in 2023, then surged by 60.3% to $372.1 million in 2024, then retreated by 21.46% to $292.2 million in 2025, then rose by 18.85% to $347.3 million in 2026.
• The last three Assets Average figures came in at $347.3 million (Q1 2026), $292.2 million (Q4 2025), and $311.7 million (Q3 2025), per Business Quant data.